Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04323748 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

Study acronym: NYMC207
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 15, 2026 (before its estimated July 31, 2026 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Jul 31, 2024 to Jul 31, 2026
    • Study completion date: Jul 31, 2025 to Jul 31, 2027
    • Site details revised
    v6
  2. Primary completion date: Jul 31, 2023 to Jul 31, 2024
    • Study completion date: Jul 31, 2024 to Jul 31, 2025
    v5
  3. Re-verified, no change to tracked fieldsv4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Sep 15, 2020 to Feb 24, 2021
    • Study sites: 0 to 1
    v3
  5. Start date: Mar 15, 2020 to Sep 15, 2020
    • Primary completion date: Dec 31, 2023 to Jul 31, 2023
    • Study completion date: Dec 31, 2023 to Jul 31, 2024
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine if a dose dense administration of Rituximab in newly diagnosed acute immune thrombocytopenic purpura (ITP) and determine relapse rate following this treatment. Correlative studies will be performed as outlined in the appendices. Quality of Life will be measured using the KIT as outlined in the protocol.
Trial Details
NCT Number NCT04323748
Lead Sponsor New York Medical College
Conditions
(from sponsor)		 Immune Thrombocytopenic Purpura
Related terms Purpura, Thrombocytopenic, Idiopathic
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov